Pfizer Launches First-Line Treatment for Mutant Metastatic Colourectal Cancer
Pfizer has introduced BRAFTOVI® (encorafenib), in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 (comprising fluorouracil, leucovorin, and oxaliplatin), as a first-line treatment for patients with metastatic colourectal cancer (mCRC) harbouring a BRAF V600E mutation.
BRAFTOVI, an oral small molecule kinase inhibitor, specifically targets the BRAF V600E mutation. This mutation triggers abnormal activation of the MAPK signalling pathway (RAS-RAF-MEK-ERK), which is implicated in the progression of certain cancers, including colourectal cancer.
This new treatment is approved for use in patients with BRAF V600E-mutant mCRC, as identified by an FDA-approved test, and combines BRAFTOVI with cetuximab and mFOLFOX6.
The approval is backed by results from the Phase 3 BREAKWATER trial, which demonstrated a statistically significant and clinically meaningful improvement in response rate and durability in treatment-naïvoe patients.
As the first and only treatment regimen to include BRAF-targeted therapy for this specific patient group, BRAFTOVI delivers rapid and durable response rates. This breakthrough marks a significant step forward in disease management, bringing renewed hope to patients and their families.
The approval of this novel combination therapy marks a significant milestone in the fight against BRAFV600E-mutant metastatic colourectal cancer, particularly for untreated patients. It signifies a promising step forward for the medical community’s ongoing efforts to combat this disease.
